The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03192618 |
Recruitment Status :
Recruiting
First Posted : June 20, 2017
Last Update Posted : June 20, 2017
|
Sponsor:
Sun Yat-sen University
Information provided by (Responsible Party):
Rong-ping Guo, Sun Yat-sen University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | December 31, 2022 |
Estimated Study Completion Date : | December 31, 2024 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):